Monitoring of Heparin and Low Molecular Weight Heparin with Capillary and Venous Whole Blood

Summary

A method for determination of antifactor Xa-like activity in capillary whole blood obtained from the fingertip is described, which employs the Heptest coagulation assay. Values obtained with capillary whole blood are compared to values of corresponding plasma and venous whole blood samples. Normal values in plasma, venous whole blood, and capillary blood from the fingertip were 17.1 ± 2.1, 10.0 ± 1.3 and 10.4 ± 1.3 sec, respectively. The intraindividual coefficients of variations range from 0.4 to 1.8% in all assays. The day to day coefficient of variation of normal values ranged between 0.8 and 2.0% for all assays. The within assay coefficients of variation ranged from 3.0 to 7.7% for whole blood samples and from 1.5 to 2.2% for plasma samples after addition of no, 0.2 or 1.0 units of normal or LMW heparin to the samples. After administration of heparin or LMW heparin in healthy persons the coagulation values of the different coagulation assay systems displayed coefficients of correlation betweell r = 0.87 and r = 0.95. Correlation coefficients between the coagulation tests and the S 2222 chromogenic substrate method ranged from r = 0.77 to r = 0.92. In patients, who received LMW heparin for prophylaxis of thromboembolism the coagulation assay correlated between r = 0.78 and 0.92. The coagulation assays and the S 2222 method displayed coefficients of correlation between r = 0.74 and r = 0.83. The data indicate that Heptest sensitively measures antifactor Xa-like activity in capillary whole blood as well as venous whole blood samples containing low quantities of heparin or LMW heparin.

Keywords

Heparin - Low molecular weight heparin - Coagulation assays - Chromogenic substrate assays

• References

• 1 Kakkar VV, Djazaeri B, Fok J, Fletcher M, Scully MF, Westwick J. Low-molecular weight heparin and prevention of postoperative deep vein thrombosis. Br Med J 1982; 284: 375-379
• 2 Bergqvist D, Burmark US, Frisell J, Hallbook T, Lindblad B, Risberg B, Tomgren S, Wallin G. Low molecular weight heparin once daily compared with conventional low-dose heparin twice daily. A prospective double-blind multicentre trial on prevention of postoperative thrombosis. Br J Surg 1986; 73: 204-208
• 3 Turpie AG G, Levine MN, Hirsh J, Carter CJ, Jay RM, Powers PJ, Andrew M, Hull RD, Gent M. A randomized controlled trial of a low-molecular weight heparin (Enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery. N Engl J Med 1986; 315: 925-929
• 4 Dahan R, Houlbert D, Gaulin C, Cuzin E, Viltart C, Woler M, Segrestaa JM. Prevention of deep vein thrombosis in elderly medical in patients by a low molecular weight heparin: A randomized doubleblind trial. Haemostasis 1986; 16: 159-164
• 5 Harenberg J, Leber G, Augustin J, Raedsch R, Schwarz F, Stiehl A, Zimmermann R. Long term prophylaxis of thromboembolism with low molecular weight heparin. Klin Wschr 1987; 65: 331-337
• 6 Harenberg J, Kallenbach B, Martin U, Zimmermann R. Randomized double blinded study of normal and a low molecular weight heparin in general medical patients. Thromb Haemostas 1987; 58: 381 (Abstr 1392)
• 7 Holm HA, Ly B, Handeland GF, Abildgaard U, Arnesen KE, Gottschalk P, Hoeg V, Aandahl M, Haugen K, Laerum F, Scheel B, Sortland O, Vinje B. Subcutaneous heparin treatment of deep venous thrombosis: A comparison of unfractionated and low molecular weight heparin. Haemostasis 1986; 16: 30-37
• 8 Janvier G, Winnock S, Dugrais G, Vallet A, Dardel E, Serise JM, Calen S, Vergnes C, Toulemonde F. Treatment of deep venous thrombosis with a very low molecular weight heparin fragment (CY 222). Haemostasis 1987; 7: 49-58
• 9 Teien AN, Bjornson J. Heparin elimination in uraemic patients on haemo-dialysis. Scand J Haematol 1976; 17: 29-35
• 10 Follea G, Laville M, Pozet N, Dechavann M. Pharmacokinetic studies of standard heparin and low molecular weight heparin in patients with chronic renal failure. Haemostasis 1986; 16: 147-151
• 11 Vieweg WV R, Piscatelli RL, Houser JJ H, Proulx RA. Complications of intravenous administration of heparin in elderly women. JAMA 1970; 213: 1303-1306
• 12 Basu D, Gallus A, Hirsh J, Cade J. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med 1972; 287: 324-327
• 13 Teien AN, Lie M. Heparin assay in plasma: A comparison of five clotting methods. Thromb Res 1975; 7: 777-788
• 14 Teien AN, Abildgaard U, Hook M, Lindahl U. Anticoagulant activity of heparin: assay of bovine, human and porcine preparations by amidolytic and clotting methods. Thromb Res 1977; 11: 107-117
• 15 Yin ET, Wessler S, Butler J. Plasma heparin: A unique, practical, submicrogram-sensitive assay. J Lab Clin Med 1973; 81: 298-310
• 16 Harenberg J, Giese Ch, Knodler A, Zimmermann R. Antifactor Xa clotting method for heparin and low molecular weight heparins. Arztl Lab 1986; 32: 181-184
• 17 Owren PA. Thrombotest - a new method for controlling anticoagulant therapy. Lancet 1959; 02: 754-756
• 18 Harenberg J. Modified anti-factor Xa chromogenic substrate assay for heparin and low molecular weight heparin. Arztl Lab 1987; 33: 39-41
• 19 Walenga JM, Fareed J, Hoppensteadt D, Emanuele RM. In vitro evaluation of heparin fractions: old vs new methods. CRC Crit Rev in Clin Lab Sci 1986; 22: 361-389
• 20 Harenberg J, Giese Ch, Knodler A, Zimmermann R. Comparative study on a new one-stage clotting assay for heparin and its low molecular weight derivatives. Haemostasis 1989 19. (in press)